DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Morgan Stanley - 2 Morgan - 2 Thibault Boutherin - 2 — CNBC's Michael Bloom - 2 Morgan Stanley's - 1 ASML Morgan Stanley - 1 Lee Simpson - 1 ASML's - 1
Top related locs:
U.S Europe TSMC Euronext Amsterdam United States Frankfurt argenx Novo
Top related orgs:
Merck - 2 Apple - 1 Euronext - 1 Nasdaq - 1 London Stock Exchange - 1 Euronext Paris - 1 American Depository - 1 SAP - 1

Search resuls for: "Boutherin"


2 mentions found


☆ 'AI shopping list': Morgan Stanley names its top global picks to play the AI theme
  + stars: | 2024-08-13 | by ( Amala Balakrishner | In Amala-Balakrishner | ) www.cnbc.com   time to read: +4 min
The buzz around artificial intelligence may have quietened after a volatile week for some of the sector's biggest names, but Morgan Stanley continues to see promise in a raft of European stocks. Morgan Stanley's "European AI shopping list" includes names ranging from semiconductor equipment and data center plays to software and healthcare companies. Morgan Stanley has a target price of 1,000 euros ($1,092) on the stock, giving it over 27.5% potential upside. Segro Morgan Stanley describes British REIT Segro as the "landlord of Europe's largest cluster of data centers." Morgan Stanley has a target price of 224 euros on the stock, giving it around 18.3% upside potential.
Persons: Morgan Stanley, Morgan Stanley's, ASML Morgan Stanley, Lee Simpson, ASML's, Simpson, Segro Morgan Stanley, Segro, Bart Gysens, SAP Morgan Stanley, Adam Wood, Merck KGaA, Morgan, Thibault Boutherin, Boutherin, — CNBC's Michael Bloom Organizations: Apple, Euronext, Nasdaq, London Stock Exchange, Euronext Paris, American Depository, SAP, Frankfurt Stock Exchange, New York Stock Exchange, Merck, EMD Group, Canada, Merck KGaA's Electronics Locations: Europe, TSMC, Euronext Amsterdam, U.S, United States, Frankfurt
☆ Morgan Stanley likes biopharma as a defensive play — giving one stock 119% upside
  + stars: | 2024-01-22 | by ( Ganesh Rao | ) www.cnbc.com   time to read: +3 min
The biopharmaceutical sector is expected to offer a safe haven from macroeconomic and earnings concerns ahead of final quarterly results from companies, according to Morgan Stanley. Morgan Stanley, however, cautioned that the outlook for drug pricing reform in the U.S. poses risks for the sector. Shares of Indivior , argenx , AstraZeneca , Merck , Lonza, Sweden's Sobi, Novo Nordisk and Sandoz Group were among those listed by Morgan Stanley with a "buy" rating. In a bull case where Sublocade hits $2.2 billion in sales by 2030, Morgan Stanley sees shares rising further to 3,500 British pence. Novo Nordisk Shares of Novo Nordisk , a leader in diabetes and obesity drugs, offer a 9.4% upside, according to Morgan Stanley.
Persons: Morgan Stanley, Mark D Purcell, Sweden's, Sublocade, Thibault Boutherin, Morgan, — CNBC's Michael Bloom Organizations: Barclays, Bank of America, AstraZeneca, Merck, Lonza, Novo Nordisk, Sandoz Group, AstraZeneca AstraZeneca, British pharma, EU Locations: U.S, argenx, Novo, Indivior
0 next >>
Total: 2